John S Kim1,2, Michael A Thomashow1,3, Natalie H Yip1, Kristin M Burkart1, Christian M Lo Cascio1, Daichi Shimbo1, R Graham Barr1,4. 1. Department of Medicine, Columbia University Irving Medical Center, New York, New York, United States. 2. Department of Medicine, University of Virginia School of Medicine, Charlottesville, Virginia, United States. 3. Kaiser Permanante San Francisco Medical Center, San Francisco, California, United States. 4. Department of Epidemiology, Mailman School of Public Health, Columbia University Irving Medical Center, New York, New York, United States.
Abstract
RATIONALE: Studies suggest a pathogenic role of endothelial dysfunction in chronic obstructive lung disease (COPD). Omega-3 (n-3) polyunsaturated fatty acid (PUFA) supplementation improves endothelial function in other diseases but has not been examined in COPD. OBJECTIVE: We hypothesized that n-3 PUFA supplementation would improve systemic endothelial function in COPD. We performed a pilot randomized, placebo-controlled, double-blind, phase 2 superiority trial (NCT00835289). METHODS: Adults with moderate and severe stable COPD (79% with emphysema on computed tomography [CT]) were randomized to high-dose fish oil capsules or placebo daily for 6 months. The primary endpoint was percentage change in brachial artery flow-mediated dilation (FMD) from baseline to 6 months. Secondary endpoints included peripheral arterial tonometry, endothelial microparticles (EMPs), 6-minute walk distance, respiratory symptoms, and pulmonary function. RESULTS: Thirty-three of 40 randomized participants completed all measurements. Change in FMD after 6 months did not differ between the fish oil and placebo arms (-1.1%, 95% CI -5.0-2.9, p=0.59). CD31+ EMPs increased in the fish oil arm (0.9%, 95% CI 0.1-1.7, p=0.04). More participants in the fish oil arm reported at least a 4-point improvement in the St George's Respiratory Questionnaire (SGRQ) compared to placebo (8 versus 1; p=0.01). There were no significant changes in other secondary endpoints. There were 4 serious adverse events determined to be unrelated to the study (3 in the fish oil arm and 1 in the placebo arm). CONCLUSION: Randomization to n-3 PUFAs for 6 months did not change systemic endothelial function in COPD. Changes in EMPs and SGRQ suggest n-3 PUFAs might have biologic and clinical effects that warrant further investigation. JCOPDF
RATIONALE: Studies suggest a pathogenic role of endothelial dysfunction in chronic obstructive lung disease (COPD). Omega-3 (n-3) polyunsaturated fatty acid (PUFA) supplementation improves endothelial function in other diseases but has not been examined in COPD. OBJECTIVE: We hypothesized that n-3 PUFA supplementation would improve systemic endothelial function in COPD. We performed a pilot randomized, placebo-controlled, double-blind, phase 2 superiority trial (NCT00835289). METHODS: Adults with moderate and severe stable COPD (79% with emphysema on computed tomography [CT]) were randomized to high-dose fish oil capsules or placebo daily for 6 months. The primary endpoint was percentage change in brachial artery flow-mediated dilation (FMD) from baseline to 6 months. Secondary endpoints included peripheral arterial tonometry, endothelial microparticles (EMPs), 6-minute walk distance, respiratory symptoms, and pulmonary function. RESULTS: Thirty-three of 40 randomized participants completed all measurements. Change in FMD after 6 months did not differ between the fish oil and placebo arms (-1.1%, 95% CI -5.0-2.9, p=0.59). CD31+ EMPs increased in the fish oil arm (0.9%, 95% CI 0.1-1.7, p=0.04). More participants in the fish oil arm reported at least a 4-point improvement in the St George's Respiratory Questionnaire (SGRQ) compared to placebo (8 versus 1; p=0.01). There were no significant changes in other secondary endpoints. There were 4 serious adverse events determined to be unrelated to the study (3 in the fish oil arm and 1 in the placebo arm). CONCLUSION: Randomization to n-3 PUFAs for 6 months did not change systemic endothelial function in COPD. Changes in EMPs and SGRQ suggest n-3 PUFAs might have biologic and clinical effects that warrant further investigation. JCOPDF
Authors: Joaquin J Jimenez; Wenche Jy; Lucia M Mauro; Carl Soderland; Lawrence L Horstman; Yeon S Ahn Journal: Thromb Res Date: 2003-02-15 Impact factor: 3.944
Authors: Raphaëlle Varraso; R Graham Barr; Walter C Willett; Frank E Speizer; Carlos A Camargo Journal: Am J Clin Nutr Date: 2014-11-26 Impact factor: 7.045
Authors: C H Strey; J M Young; J H Lainchbury; C M Frampton; M G Nicholls; A M Richards; R S Scott Journal: Heart Date: 2006-05-18 Impact factor: 5.994
Authors: Ka He; Kiang Liu; Martha L Daviglus; Nancy Swords Jenny; Elizabeth Mayer-Davis; Rui Jiang; Lyn Steffen; David Siscovick; Michael Tsai; David Herrington Journal: Am J Cardiol Date: 2009-03-04 Impact factor: 2.778
Authors: Michael A Thomashow; Daichi Shimbo; Megha A Parikh; Eric A Hoffman; Jens Vogel-Claussen; Katja Hueper; Jessie Fu; Chia-Ying Liu; David A Bluemke; Corey E Ventetuolo; Margaret F Doyle; R Graham Barr Journal: Am J Respir Crit Care Med Date: 2013-07-01 Impact factor: 21.405
Authors: Noyan Gokce; John F Keaney; Liza M Hunter; Michael T Watkins; Zoran S Nedeljkovic; James O Menzoian; Joseph A Vita Journal: J Am Coll Cardiol Date: 2003-05-21 Impact factor: 24.094